Showing 2401-2410 of 3315 results for "".
- Nidek Introduces Phantom Open-field Refraction Systemhttps://modernod.com/news/nidek-introduces-phantom-open-field-refraction-system/2485460/Nidek announced the launch of the Phantom Open-field Refraction System. Phantom is an open-field binocular refraction system that eliminates the use of physical lenses entirely—placing nothing in front of the patient’s eyes. According to Nidek, by removing this lon
- Optical Industry Coalition Urges Congress to Address Tariffs Driving Up Cost of Vision Carehttps://modernod.com/news/optical-industry-coalition-urges-congress-to-address-tariffs-driving-up-cost-of-vision-care/2485459/Key Takeaways Optical industry leaders warned Congress that current trade policies are driving up t
- Tickets and Sponsorships Available for 2026 Prevent Blindness Person of Vision Award Gala Honoring Jim McGrannhttps://modernod.com/news/tickets-and-sponsorships-available-for-2026-prevent-blindness-person-of-vision-award-gala-honoring-jim-mcgrann/2485427/Prevent Blindness has announced that tickets and sponsorship opportunities remain available for the 2026 Prevent Blindness Person of Vision Award gala, which will honor Jim McGrann, CEO of Advancing Eyecare, for his decades of leadership and dedication to improving
- Orbis International Appoints Kathleen Sherwin as New President and CEOhttps://modernod.com/news/orbis-international-appoints-kathleen-sherwin-as-new-president-and-ceo/2485326/Global nonprofit organization Orbis International has named Kathleen Sherwin as its new President and Chief Executive Officer, effective immediately. Ms. Sherwin arrives at Orbis with more than 25 years of leadership experience
- Vision Expo 2026 Marks 40 Years With Expanded Education Experiencehttps://modernod.com/news/vision-expo-2026-marks-40-years-with-expanded-education-experience/2485286/Produced by RX and The Vision Council, Vision Expo is celebrating its 40th year in 2026 with an enhanced educational conference designed to deliver greater access, flexibility and real-world learning for vision care professionals.
- Samsung Bioepis to Regain European Commercial Rights for Ophthalmology Biosimilars from Biogenhttps://modernod.com/news/samsung-bioepis-to-regain-european-commercial-rights-for-ophthalmology-biosimilars-from-biogen/2484299/Samsung Bioepis has entered into an Asset Purchase Agreement (APA) with Biogen concerning the transfer of two ophthalmology assets: Byooviz (ranibizumab) and Opuviz (aflibercept)—both biosimilars referencing leading treatments for retinal disea
- Regeneron Delays Regulatory Submission for Eylea HD Pre-Filled Syringe After CRLhttps://modernod.com/news/regeneron-delays-regulatory-submission-for-eylea-hd-pre-filled-syringe-after-crl/2484294/In its third quarters earnings filing, Regeneron said it received another complete response letter (CRL) from the FDA for its pre-filled syringe supplemental BLA (sBLA) for Eylea HD (aflibercept injection 8 mg). The sole approvability issue cited in the CRL relates to unresolved inspection findin
- Eli Lilly Enters Ophthalmology Sector with Acquisition of Adverum Biotechnologieshttps://modernod.com/news/eli-lilly-enters-ophthalmology-sector-with-acquisition-of-adverum-biotechnologies/2484212/Eli Lilly and Company and Adverum Biotechnologies announced that they have entered into a definitive agreement for Lilly to acquire Adverum Biotechnologies, including its lead gene therapy product candidate, Ixo-vec. I
- FDA Issues CRL to Sydnexis for SYD-101 in Pediatric Myopiahttps://modernod.com/news/fda-does-not-approve-sydnexis-syd-101-in-pediatric-myopia/2484210/The FDA has issued a complete response letter (CRL) for Sydnexis' new drug application (NDA) for SYD-101, a proprietary 0.01% atropine formulation designed to slow the progression of myopia in children. T
- FDA Clears Complement Therapeutics’ IND Application for CTx001 Gene Therapy in GAhttps://modernod.com/news/fda-clears-complement-therapeutics-ind-application-for-ctx001-gene-therapy-in-ga/2484178/Complement Therapeutics has announced that the FDA has cleared its investigational new drug (IND) application for CTx001, the company’s lead gene therapy candidate. The clearance paves the way for the initiation of Opti-GAIN, a phase 1/2 clinic